Key role of the kidney in the regulation of fibroblast growth factor 23

Kidney International

Volumn 88, Issue 6, 2015, Pages 1304-1313

  Mace, Maria L ^a   Gravesen, Eva ^a   Hofman Bang, Jacob ^a   Olgaard, Klaus ^a   Lewin, Ewa ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acute uremia; Calcium; FGF23; FGFR; Parathyroid hormone; Phosphate

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; PARATHYROID HORMONE; RECOMBINANT FIBROBLAST GROWTH FACTOR 23; RECOMBINANT GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; HALF LIFE TIME; HOMEOSTASIS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY ARTERY; KIDNEY FUNCTION; KIDNEY VEIN; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; UREMIA;

EID: 84951570571     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.231     Document Type: Article

References (91)

1. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
2. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989
3. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
4. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
5. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
6. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
7. Martin A, David V, Quarles LD. Regulation and Function of the FGF23/ Klotho Endocrine Pathways. Physiol Rev 2012; 92: 131-155
8. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276
9. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
10. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980
11. Zhang M, Hsu R, Hsu CY et al. FGF-23 and PTH levels in patients with acute kidney injury: a cross-sectional case series study. Ann Intensive Care 2011; 1: 21
12. Leaf DE, Wolf M, Waikar SS et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 2012; 7: 1217-1223
13. Christov M, Waikar SS, Pereira RC et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 2013; 84: 776-785
14. Fukumoto S. Post-translational modification of fibroblast growth factor 23. Ther Apher Dial 2005; 9: 319-322
15. Yamashita T. Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 2005; 9: 313-318
16. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone 2004; 35: 1192-1199
17. Yoshiko Y, Wang H, Minamizaki T et al. Mineralized tissue cells are a principal source of FGF23. Bone 2007; 40: 1565-1573
18. Tagliabracci VS, Engel JL, Wiley SE et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 2014; 111: 5520-5525
19. Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297: F282-F291
20. Yan X, Yokote H, Jing X et al. Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 2005; 10: 489-502
21. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314: 409-414
22. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293: F1577-F1583
23. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568
24. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503-533
25. Martin A, Liu S, David V et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 2011; 25: 2551-2562
26. White KE, Cabral JM, Davis SI et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 2005; 76: 361-367
27. Wohrle S, Bonny O, Beluch N et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 2011; 26: 2486-2497
28. Wu AL, Feng B, Chen MZ et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PloS One 2013; 8: e57322
29. Barthel TK, Mathern DR, Whitfield GK et al. 1,25-Dihydroxyvitamin D3/ VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 2007; 103: 381-388
30. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26: 75-84
31. Inoue Y, Segawa H, Kaneko I et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005; 390: 325-331
32. Kolek OI, Hines ER, Jones MD et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289: G1036-G1042
33. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
34. Saini RK, Kaneko I, Jurutka PW et al. 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin
35. Calcif.Tissue Int 2013; 92: 339-353
36. Saji F, Shigematsu T, Sakaguchi T et al. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol 2010; 299: F1212-F1217
37. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095
38. Andrukhova O, Smorodchenko A, Egerbacher M et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 2014; 33: 229-246
39. Gravesen E, Mace ML, Hofman-Bang J, Olgaard K, Lewin E. Circulating FGF23 levels in response to acute changes in plasma Ca(2+). Calcif Tissue Int 2014; 95: 46-53
40. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012; 23: 1190-1197
41. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
42. Ben Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008
43. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125-1135
44. Galitzer H, Ben Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218
45. Hofman-Bang J, Martuseviciene G, Santini MA, Olgaard K, Lewin E. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78: 1119-1127
46. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77: 292-298
47. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131
48. Kumata C, Mizobuchi M, Ogata H et al. Involvement of alpha-Klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol 2010; 31: 230-238
49. Martuseviciene G, Hofman-Bang J, Clausen T, Olgaard K, Lewin E. The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int 2011; 79: 742-748
50. Ohkido I, Yokoyama K, Imura A, Utsunomiya Y, Hosoya T, Nabeshima Y. Persistent alpha-Klotho (a-Kl) expression in the parathyroid glands of patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2010; 25: 1007-1008
51. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688
52. Wesseling-Perry K, Harkins GC, Wang HJ et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010; 95: 2772-2780
53. Christov M, Juppner H. Insights from genetic disorders of phosphate homeostasis. Semin Nephrol 2013; 33: 143-157
54. Meir T, Durlacher K, Pan Z et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 2014; 86: 1106-1115
55. Rhee Y, Bivi N, Farrow E et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011; 49: 636-643
56. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
57. Gupta J, Mitra N, Kanetsky PA et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946
58. Munoz MJ, Isakova T, Ricardo AC et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162
59. Zanchi C, Locatelli M, Benigni A et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One 2013; 8: e70775
60. Spichtig D, Zhang H, Mohebbi N et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 2014; 85: 1340-1350
61. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27: 38-46
62. Lopez I, Rodriguez-Ortiz ME, Almaden Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80: 475-482
63. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585
64. Shimada T, Muto T, Urakawa I et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143: 3179-3182
65. Lewin E, Olgaard K. Vitamin D in CKD: a continuous challenge. NephSAP 2010; 9: 273-277
66. Khosravi A, Cutler CM, Kelly MH et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007; 92: 2374-2377
67. Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89: 3979-3982
68. Rowland L, Tozer TN. Clinical Pharmacokinetics and Applications, 3rd edn. Lippincott Williams & Wilkins: Philadelphia, PA, USA, 1995
69. Ito N, Fukumoto S, Takeuchi Y et al. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 2007; 25: 419-422
70. Scanni R, vonRotz M, Jehle S, Hulter HN, Krapf R. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol 2014; 25: 2730-2739
71. Arai-Nunota N, Mizobuchi M, Ogata H et al. Intravenous phosphate loading increases fibroblast growth factor 23 in uremic rats. PLoS One 2014; 9: e91096
72. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549
73. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate-and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005; 36: 971-977
74. Zhang S, Gillihan R, He N et al. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney Int 2013; 84: 713-721
75. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146: 5358-5364
76. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
77. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006; 21: 1187-1196
78. Isakova T, Barchi-Chung A, Enfield G et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013; 8: 1009-1018
79. Nishida Y, Taketani Y, Yamanaka-Okumura H et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006; 70: 2141-2147
80. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524
81. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM. Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol 2011; 6: 383-389
82. Isakova T, Gutierrez OM, Smith K et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591
83. Quinn SJ, Thomsen AR, Pang JL et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 2013; 304: E310-E320
84. Parfitt AM. Calcium Homeostasis. In: Born GVR, Cuatrecasas P, Herken H, Melmon K (eds). Handbook of Experimental Pharmacology, Vol. 107, Springer-Verlag: Berlin, Germany, 1993 pp1-65
85. Nordholm A, Mace ML, Gravesen E, Olgaard K, Lewin E. A potential kidney-bone axis involved in the rapid minute-to-minute regulation of plasma Ca(2+). BMC Nephrol 2015; 16: 29
86. Wang W, Lewin E, Olgaard K. Rate-dependency of calcitonin secretion in response to increased plasma Ca2+. Eur J Clin Invest 2002; 32: 669-673
87. Wang W, Lewin E, Olgaard K. Role of calcitonin in the rapid minute-tominute regulation of plasma Ca2+ homeostasis in the rat. Eur J Clin Invest 2002; 32: 674-681
88. Wang W, Lewin E, Olgaard K. Parathyroid hormone is not a key hormone in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in rats. Eur J Clin Invest 1999; 29: 309-320
89. Wang W, Lewin E, Olgaard K. 1,25(OH)2D3 only affects long-term levels of plasma Ca2+ but not the rapid minute-to-minute plasma Ca2+ homeostasis in the rat. Steroids 1999; 64: 726-734
90. Lewin E, Colstrup H, Pless V, Ladefoged J, Olgaard K. A model of reversible uremia employing isogenic kidney transplantation in the rat. Reversibility of secondary hyperparathyroidism. Scand J Urol Nephrol 1993; 27: 115-120
91. Lewin E, Wang W, Olgaard K. Rapid recovery of plasma ionized calcium after acute induction of hypocalcaemia in parathyroidectomized and nephrectomized rats. Nephrol Dial Transplant 1999; 14: 604-609.